Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

Date: May 1, 2013
Pages: 301
Price:
US$ 2,100.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C189DEB1582EN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:
  • Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA)
  • G-CSF & GM-CSF
  • Thrombopoietin & Thrombopoiesis Stimulating Agents
  • Interferon
  • Insulin
  • Coagulation Factors
  • Human Growth Hormone (hGH)
  • FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)
  • Thrombolytics & Fibrinolytics
  • Enzyme Replacement Therapies
Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets. Competitor projects are listed in a tabular format providing Information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) ERYTHROPOIESIS STIMULATING AGENTS (ESA)

First generation epoetins in regulated markets
Second generation epoetins in regulated markets
Epoetin biosimilars in regulated markets
Darbepoetin biosimilars in regulated markets
Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets
Next generation small molecule Erythropoiesis Stimulating Agents
First generation EPO in less regulated markets (Latin America; Africa; Asia; RoW)
Darbepoietin biosimilars in less regulated markets
Next generation biologic ESAs in less regulated markets

2) G-CSF AND GM-CSF

2012 Sales of Branded G-CSF Products in Regulated Markets
1st Generation Branded G-CSF Products in Regulated Markets
Biosimilar 1st Generation G-CSF Products in Regulated Markets
Next Generation Branded G-CSF Products in Regulated Markets
Biosimilar Next Generation G-CSF Products in Regulated Markets
1st Generation G-CSF Products in Non-Regulated Markets: India
1st Generation G-CSF Products in Non-Regulated Markets: China & Taiwan
1st Generation G-CSF Products in Non-Regulated Markets – Korea
1st Generation G-CSF Products in Non-Regulated Markets – Latin America
1st Generation G-CSF Products in Non-Regulated Markets: Other Territories
Next Generation G-CSF Products in Non-Regulated Markets
1st and Next Generation GM-CSF Products in Regulated Markets
1st and Next Generation GM-CSF Products in Non-Regulated Markets

3) THROMBOPOIESIS-STIMULATING AGENTS (TPO; IL-11)

Thrombopoietin receptor (TPO-R) activators
Interleukin-11 (IL-11) receptor activators
Small molecule TPO-R Agonists
Corporate TPO/IL-11 Receptor Agonist Product Portfolios and R&D Pipelines

4) INTERFERON

a) INTERFERON alpha
##Interferon alpha sales 2012 of branded products in regulated markets
##1st generation Interferon alpha-2a in regulated markets
##1st generation Interferon alpha-2a in non-regulated markets
##Next generation Interferon alpha-2a in regulated markets
##Next generation Interferon alpha-2a in non-regulated markets and biosimilars
##1st generation Interferon alpha-2b in regulated markets
##1st generation Interferon alpha-2b in non-regulated markets and biosimilars
##Next generation Interferon alpha-2b in regulated markets
##Next generation Interferon alpha-2b in non-regulated markets and biosimilars
##Other Interferon alpha sub-types
##Interferon alpha with not specified sub-type – 1/2
##Purified natural human interferon alpha
b) Consensus INTERFERONs
c) INTERFERON beta
##Interferon beta sales 2012 of branded products in regulated markets
##1st generation Interferon beta-1a in regulated markets
##1st generation Interferon beta-1a in non-regulated markets and biosimilars
##1st generation Interferon beta-1b in regulated markets
##1st generation Interferon beta-1b in non-regulated markets and biosimilars
##1st generation Interferon beta with not disclosed sub-type
##Next generation Interferon beta in regulated markets
##Purified natural human interferon beta
d) INTERFERON gamma
e) Other INTERFERONs

5) INSULIN

2012 Sales of branded recombinant human insulins in regulated markets
2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets
2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets
Rhu insulin (2nd generation) in regulated markets
Biosimilar rhu insulin (2nd generation) in regulated markets
Rhu insulin analogs (3rd generation) in regulated markets
Biosimilar rhu insulin analogs (3rd generation) in regulated markets
Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)
Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)
Combinations of modern basal and prandial insulin & analogs (4th generation)
Combinations of insulin & GLP-1 agonist (4th generation)
Other combinations with insulin
Oral and Transbuccal Insulins (5th generation)
Inhaled and transdermal insulin
Novel approaches for insulin therapy
Rhu insulin (2nd generation) in non-regulated markets: India
Rhu insulin (2nd generation) in non-regulated markets: China
Rhu insulin (2nd generation) in non-regulated markets: Other Territories
Modern insulin analogs (3rd generation) in non-regulated markets

6) COAGULATION FACTORS

Sales of Recombinant Coagulation Factors for Hemophilia in 2012
Coagulation Factor VIII
Coagulation Factor IX
Coagulation Factor VII
Coagulation Factors for Willebrand Disease
Fibrinogen
Factors XI, X and XIII
Alternative Procoagulants & Adjuncts
Human Plasma-Derived Prothrombin Complex Concentrates
Gene Therapy of Hemophilia
Topical Human Plasma-Derived Fibrinogen and Thrombin Products
Topical Plasma-Derived Thrombin Products
Topical Recombinant Human Factor II (Prothrombin)
Alternative Topical Hemostats

7) HUMAN GROWTH HORMONE (HGH)

2012 Sales of Branded Somatropin Products in Regulated Markets
2012 Sales of Selected Somatropin Products in Non-Regulated Markets
1st Generation: Somatropin in Regulated Markets
1st Generation: Biosimilar Somatropin in Regulated Markets
2nd Generation: Injectable Somatropin in Slow-release Formulation in Regulated Markets
2nd Generation: Injectable Long-acting Somatropin in Regulated Markets
2nd Generation: Injection-Free Somatropin in Regulated Markets
1st Generation: Somatropin Products in Non-Regulated Markets
2nd Generation: Injectable Long-Acting Somatropin Products in Non-Regulated Markets

8) FSH, HCG AND LH - ASSISTED REPRODUCTIVE TECHNOLOGY (ART)

Urinary FSH-Containing Products: Menotropins
Recombinant Menotropins
1st Generation Purified Human Urinary FSH
2nd Generation Recombinant Human FSH
Biosimilar Recombinant Human FSH
2nd Generation Rhu FSH in Non-Regulated Markets
3rd Generation Rhu FSH
Purified Urinary Human Choriogonadotropin (hCG)
Recombinant Human Choriogonadotropin (rhCG)
Recombinant Human Luteinizing Hormone (rhLH)
hCG Receptor Agonist

9) THROMBOLYTICS & FIBRINOLYTICS

Non-fibrin selective (1st generation) Fibrinolytics
Fibrin selective wild-type t-PA-based Fibrinolytics
Fibrin selective engineered t-PA-based Fibrinolytics
Non-t-PA-based Fibrinolytics
Plasmin-based Fibrinolytics
Adjunctive therapy to Fibrinolytics
Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets

10) ENZYME REPLACEMENT THERAPIES

Gaucher Disease
Fabry Disease
Pompé Disease
Hunter Disease (MPS II)
Niemann Pick Diseases
Mucopolysaccharidosis I (MPS I)
San Filippo Syndrome (MPS IIIA)
Morquio Syndrome (MPS IVA)
Mucopolysaccharidosis VI (MPS VI)
Tay-Sachs Disease
Chronic Deficiency of Adenosine Deaminase
Phenylketonuria / Hyperphenylalaninemia
Other Enzyme Replacement Therapies
Exocrine Pancreatic Insufficiency: Porcine-Derived ERT
Exocrine Pancreatic Insufficiency: Recombinant ERT
Others
Skip to top


Ask Your Question

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: